ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models von Smith, Roger A, Zammit, David J, Damle, Nitin K, Usansky, Helen, Reddy, Sanjeeva P, Lin, Jun-Hsiang, Mistry, Mahesh, Rao, Niranjan S, Denis, Louis J, Gupta, Sandeep

Volltext

The complex pathology of trinucleotide repeats von Reddy, P Sanjeeva, Housman, David E

Volltext

Abstract B109: ASN004, a novel 5T4-targeted Dolaflexin ADC, causes complete and durable tumor regression in a variety of tumor xenograft models von Smith, Roger A., Zammit, David J., Reddy, Sanjeeva P.

Volltext

Abstract 43: ASN004, a novel 5T4-targeted Dolaflexin ADC, achieves complete regressions and tumor-free survivors in a broad variety of solid tumor models von Smith, Roger A., Zammit, David J., Reddy, Sanjeeva P.

Volltext

Abstract B05: ASN007, an oral ERK1/2 inhibitor, shows strong antitumor activity across a panel of KRAS subtype mutant cancer models von Reddy, Sanjeeva P., Thompson, Scott K., Usansky, Helen, Smith, Roger A., Denis, Louis, Gupta, Sandeeep

Volltext

The Epithelium-specific ETS Protein EHF/ESE-3 Is a Context-dependent Transcriptional Repressor Downstream of MAPK Signaling Cascades von Tugores, Antonio, Le, Jennifer, Sorokina, Irina, Snijders, A.J., Duyao, Mabel, Reddy, P. Sanjeeva, Carlée, Leone, Ronshaugen, Mathew, Mushegian, Arcady, Watanaskul, Tim, Chu, Sunny, Buckler, Alan, Emtage, Spencer, McCormick, Mary Kay

Volltext

Abstract 5783: Strong antitumor activity of ASN007, an oral ERK1/2 inhibitor, in PDX tumor models with MAP kinase pathway alterations including KRAS mutations von Reddy, Sanjeeva P., Rao, Niranjan S., Smith, Roger A., Thompson, Scott K., Toker, Sarper

Volltext

Abstract B150: ASN007, a novel oral ERK inhibitor, shows robust antitumor activity in RAS mutant cancer models von Reddy, Sanjeeva P., Sivanandhan, Dhanalakshmi, Dewang, Purushottam, Rao, Niranjan, Smith, Roger A., Thompson, Scott K.

Volltext

Abstract 4204: ASN002: A novel dual SYK/JAK inhibitor with strong antitumor activity in both hematological and solid tumor xenograft models von Reddy, Sanjeeva P., Rao, Niranjan, Zammit, David, Thompson, Scott K., Smith, Roger A., Denis, Louis

Volltext

Abstract 158: ASN003, a highly selective inhibitor of B-Raf and PI3 kinases, shows strong antitumor activity in B-Raf inhibitor resistant patient-derived xenograft models von Thompson, Scott K., Smith, Roger A., Rao, Niranjan, Wick, Michael J., Reddy, Sanjeeva P.

Volltext

Abstract 187: ASN0007, a potent ERK12 inhibitor with strong antitumor activity in multiple RAS mutant models von Reddy, Sanjeeva P, Sivanandhan, Dhanalakshmi, Kethiri, Raghava Reddy, Nair, Sreekala, Dewang, Purushottam, Zainuddin, Mohd, Vaithilingam, Krishnakumar, Smith, Roger A, Gupta, Sandeep, Thompson, Scott K

Volltext

Abstract 187: ASN0007, a potent ERK1/2 inhibitor with strong antitumor activity in multiple RAS mutant models von Reddy, Sanjeeva P., Sivanandhan, Dhanalakshmi, Kethiri, Raghava Reddy, Nair, Sreekala, Dewang, Purushottam, Zainuddin, Mohd, Vaithilingam, Krishnakumar, Smith, Roger A., Gupta, Sandeep, Thompson, Scott K.

Volltext

Abstract B100: ASN003, a unique B-RAF inhibitor with additional selective activity against PI3K and mTOR kinases, shows strong antitumor activity in multiple xenograft models von Thompson, Scott K., Jaleel, Mahaboobi, Nyavanandi, Vijay Kumar, Ramachandra, Murali, Subramanya, Hosahalli, Basavaraju, Aravind, Sihorkar, Vaibhav, Smith, Roger A., Rao, Niranjan, Gupta, Sandeep, Reddy, Sanjeeva P.

Volltext

Abstract 1693: ASN004, a novel 5T4-targeted Dolaflexin™ antibody drug conjugate, causes complete regression in multiple solid tumor models von Smith, Roger A., Damle, Nitin K., Reddy, Sanjeeva P., Yurkovetskiy, Alex, Bodyak, Natalya, Yin, Mao, Gumerov, Dmitry, Ter-Ovanesyan, Elena, Qin, Liu, Park, Peter U., Lowinger, Timothy B., Gupta, Sandeep

Volltext

Abstract B274: Discovery and characterization of a highly selective inhibitor of B-RAF, PI3K, and mTOR kinases with antitumor activity in B-RAF and B-RAF/PI3K pathway double mutant... von Reddy, Sanjeeva P., Jaleel, Mahaboobi, Nyavanandi, Vijay K., Ramachandra, Murali, Subramanya, Hosahalli, Basavaraju, Aravind, Sihorkar, Vaibhav, Smith, Roger A., Gupta, Sandeep, Thompson, Scott K.

Volltext

Advanced Protection for Automobiles Using MSP430 von Ravi Shankar Reddy, C., Siva Kumar Reddy, V., Vinay Simha Reddy, T., Sanjeeva Reddy, P.

Volltext

Isolation and Characterization of a Near-Haploid Human Cell Line von Kotecki, Maciej, Reddy, P.Sanjeeva, Cochran, Brent H.

Volltext

HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER von REDDY, SANJEEVA P, KETHIRI, RAGHAVA REDDY, VENKATESAN, ARANAPAKAM M, SMITH, ROGER A, HALLUR, GURULINGAPPA, DEWANG, PURUSHOTTAM M, MULAKALA, CHANDRIKA, ZAINUDDIN, MOHD, MULLANGI, RAMESH, THOMPSON, SCOTT K

Volltext bestellen

Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer von Venkatesan, Aranapakam M, Dewang, Purushottam M, Thompson, Scott K, Mulakala, Chandrika, Kethiri, Raghava Reddy, Hallur, Gurulingappa, Smith, Roger A, Reddy, Sanjeeva P

Volltext bestellen

HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER von REDDY, SANJEEVA P, KETHIRI, RAGHAVA REDDY, VENKATESAN, ARANAPAKAM M, SMITH, ROGER A, HALLUR, GURULINGAPPA, DEWANG, PURUSHOTTAM M, MULAKALA, CHANDRIKA, ZAINUDDIN, MOHD, MULLANGI, RAMESH, THOMPSON, SCOTT K

Volltext bestellen